CH451156A - Process for the preparation of the new N- (2-chloro-ethyl) -N '- (5-nitro-thiazolyl-2) -urea - Google Patents

Process for the preparation of the new N- (2-chloro-ethyl) -N '- (5-nitro-thiazolyl-2) -urea

Info

Publication number
CH451156A
CH451156A CH1103062A CH1103062A CH451156A CH 451156 A CH451156 A CH 451156A CH 1103062 A CH1103062 A CH 1103062A CH 1103062 A CH1103062 A CH 1103062A CH 451156 A CH451156 A CH 451156A
Authority
CH
Switzerland
Prior art keywords
urea
thiazolyl
new
salts
nitro
Prior art date
Application number
CH1103062A
Other languages
German (de)
Inventor
Paul Dr Schmidt
Max Dr Wilhelm
Kurt Dr Eichenberger
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Priority to CH1103062A priority Critical patent/CH451156A/en
Publication of CH451156A publication Critical patent/CH451156A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/58Nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/48Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines

Description

  

  



  Verfahren zur Herstellung des neuen   N-      äthyl)-N' (5-nitro thiazolyl-2)-harnstoffes   
Gegenstand der Erfindung ist ein Verfahren zur Herstellung des neuen N- (2-Chlor-äthyl)-N'- (5-nitro  thiazolyl-2)-harnstoffes    oder seiner Salze.



   Salze der neuen Verbindung sind z. B. Metallsalze, insbesondere   Alkali-und    Erdalkalimetallsalze, wie Natrum-,   Kalium-oder    Kalziumsalze, Ammoniumsalze oder Salze von organischen Aminen.



   Der neue Harnstoff und seine Salze besitzen antiparasitäre Eigenschaften, insbesondere gegenüber Pro  tozoen,    wie   Entamöba,      Flagellaten,    wie Trichomonaden, und Eimeria tenella, sowie gegen Schistosomen.



  Sie können entsprechende pharmakologische Anwendung am Tier finden. Die neue Verbindung eignet sich aber insbesondere zur Behandlung der durch die genannten Parasiten verursachten Erkrankungen, z. B. der Schistosomiasis, der   Amöbenruhr    oder der Amöbenhepatitis beim Menschen oder z. B. dem durch   Histomonas meleagridis    oder durch Eimeria tenella verursachten Infekt bei Tieren, z. B. zur Behandlung von   blackhead   oder der Coccidiose bei Geflügel oder Kaninchen. Die genannten Verbindungen können auch als Zwischenprodukte für die Herstellung anderer wertvoller Stoffe dienen.



   Das   erfindungsgemässe    Verfahren zur Herstellung des neuen Harnstoffes besteht darin, dass man   N- (2-chloräthyl)-N'-thiazolyl- (2)-harnstoff    in   5-Stellung    des   Thiazolrestes    nitriert.



   Die genannte Reaktion kann in üblicher Weise, in An-oder Abwesenheit von Verdünnungsmitteln, Kon  densationsmitteln    und/oder Katalysatoren, bei   ernied-    rigter, gewöhnlicher oder erhöhter Temperatur, bei normalem oder erhöhtem Druck   und/oder    unter einer Inertgasatmosphäre durchgeführt werden.



   Der verwendete Ausgangsstoff kann in an sich be  kannter    Weise hergestellt werden.



   Je nach der Arbeitsweise erhält man die neue Verbindung in freier Form oder in Form ihrer Salze. Letztere lassen sich in üblicher Weise, z. B. durch Ansäuern einer diese enthaltenden Lösung, in die freie Verbindung überführen. Diese wiederum lässt sich nach bekannten Methoden, beispielsweise durch Reaktion mit basischen Mitteln, z. B.   Metallhydroxyden    oder basischen Salzen, speziell Alkali-oder Erdalkalimetallhydroxyden, wie Natrium-,   Kalium-oder    Kalziumhydroxyd,   Alkalimeta7l. carbonaten,    wie Natriumoder Kaliumcarbonat, Ammoniak oder organischen Aminen, in die entsprechenden Salze überführen.



   Der neue Harnstoff und seine Salze können als Heilmittel, z. B. in Form pharmazeutischer Präparate, verwendet werden, welche diese Verbindung zusammen mit pharmazeutischen, organischen oder   anorgani-    schen, festen oder flüssigen Trägerstoffen, die für ente  rale,    z. B. orale, oder parenterale Gabe geeignet sind, enthalten.



   Die eingangs genannte Verbindung kann aber auch zusammen mit gebräuchlichen Futter-bzw.   Trägerstof-    fen in der Veterinärmedizin in Form von Präparaten oder als   Futter-bzw.    Futterzusatzmittel bei der Aufzucht von Tieren Verwendung finden. Vorzugsweise soll sie als Zusätze von Tierfuttermitteln, insbesondere für die Aufzucht und Haltung von Geflügel oder Kaninchen, Verwendung finden.



   Im folgenden Beispiel sind die Temperaturen in Celsiusgraden angegeben.



   Beispiel
Zu einer Lösung von 10 g   N- (2-Chlor-äthyl)-      N'- (2-thiazolyl)-harnstoff    in 100   cms Eisessig    tropft man bei   15  eine    Mischung von 7cm3 konzentrierter Salpetersäure in 15 cm3 Eisessig. Nach 2 Stunden Rühren bei   15  gibt    man 100 cm3 Wasser zu und de  kantiert    von dem ausgefallenen öl ab. Dieses wird mit wenig Alkohol versetzt ; hierauf gibt man   Isopropyl-    äther zu und   lässt    bei   40  stehen.    Nach einiger Zeit kristallisiert der   N- (2-Chlor-äthyl)-N- (5-nitro-thiazolyl)-      (2)-harnstoff    der Formel 
EMI2.1     
 in Kristallen von   f.    137-142¯ aus.



   Der als Ausgangsmaterial verwendete N- (2-Chlor äthyl)-N'- (2-thiazolyl)-hamstoff wird hergestellt durch Kochen von 15 g 2-Amino-thiazol und 16 g ¯-ChlorÏth  ylisocyanat    in 200   cm3 Äther.    Der Harnstoff fällt in weissen Kristallen vom F.   130-132  aus.  



  



  Process for the preparation of the new N-ethyl) -N '(5-nitro thiazolyl-2) urea
The invention relates to a process for the preparation of the new N- (2-chloro-ethyl) -N'- (5-nitro thiazolyl-2) urea or its salts.



   Salts of the new compound are e.g. B. metal salts, in particular alkali and alkaline earth metal salts, such as sodium, potassium or calcium salts, ammonium salts or salts of organic amines.



   The new urea and its salts have anti-parasitic properties, in particular against Pro tozoen such as Entamöba, flagellates such as Trichomonaden, and Eimeria tenella, and against Schistosomes.



  You can find appropriate pharmacological application on animals. The new compound is particularly suitable for treating the diseases caused by the parasites mentioned, e.g. B. schistosomiasis, amoebic dysentery or amoebic hepatitis in humans or z. B. the infection caused by Histomonas meleagridis or by Eimeria tenella in animals, e.g. B. for the treatment of blackhead or coccidiosis in poultry or rabbits. The compounds mentioned can also serve as intermediates for the production of other valuable substances.



   The process according to the invention for the preparation of the new urea consists in nitrating N- (2-chloroethyl) -N'-thiazolyl- (2) -urea in the 5-position of the thiazole radical.



   The reaction mentioned can be carried out in the customary manner, in the presence or absence of diluents, condensing agents and / or catalysts, at lower, ordinary or elevated temperature, at normal or elevated pressure and / or under an inert gas atmosphere.



   The starting material used can be prepared in a manner known per se.



   Depending on the mode of operation, the new compound is obtained in free form or in the form of its salts. The latter can be used in the usual way, for. B. by acidifying a solution containing them, converted into the free compound. This in turn can be determined by known methods, for example by reacting with basic agents, e.g. B. metal hydroxides or basic salts, especially alkali or alkaline earth metal hydroxides, such as sodium, potassium or calcium hydroxide, alkali metal. carbonates, such as sodium or potassium carbonate, ammonia or organic amines, are converted into the corresponding salts.



   The new urea and its salts can be used as remedies, e.g. B. in the form of pharmaceutical preparations can be used, which this compound together with pharmaceutical, organic or inorganic, solid or liquid excipients, which are for ente rale, z. B. oral or parenteral administration are suitable.



   The connection mentioned at the beginning can, however, also be used together with conventional feed or. Carriers in veterinary medicine in the form of preparations or as feed or. Find feed additives in the rearing of animals use. It should preferably be used as additives to animal feed, in particular for the rearing and keeping of poultry or rabbits.



   In the following example the temperatures are given in degrees Celsius.



   example
A mixture of 7 cm3 of concentrated nitric acid in 15 cm3 of glacial acetic acid is added dropwise at 15 cm to a solution of 10 g of N- (2-chloro-ethyl) -N'- (2-thiazolyl) -urea in 100 cms of glacial acetic acid. After stirring for 2 hours at 15, 100 cm3 of water are added and the precipitated oil is decanted off. A little alcohol is added to this; then isopropyl ether is added and allowed to stand at 40. After some time, the N- (2-chloro-ethyl) -N- (5-nitro-thiazolyl) - (2) -urea of the formula crystallizes
EMI2.1
 in crystals of f. 137-142¯ from.



   The N- (2-chloroethyl) -N'- (2-thiazolyl) -urea used as starting material is prepared by boiling 15 g of 2-amino-thiazole and 16 g of ¯-chloroethyl isocyanate in 200 cm3 of ether. The urea precipitates in white crystals from F. 130-132.

 

Claims (1)

PATENTANSPRUCH Verfahren zur Herstellung des neuen N- (2-Chlor äthyl)-N'gS-nitro-thiazolyl-2)-harnstoffes oder seiner Salze, dadurch gekennzeichnet, dass man N- (2-Chlor- äthyl)-N'-thiazolyl-(2)-harnstoff in 5-Stellung des Thiazolrestes nitriert. PATENT CLAIM Process for the preparation of the new N- (2-chloroethyl) -N'gS-nitro-thiazolyl-2) urea or its salts, characterized in that N- (2-chloroethyl) -N'-thiazolyl- (2) urea nitrated in the 5-position of the thiazole radical. UNTERANSPRUCHE 1. Verfahren nach Patentanspruch, dadurch ge kennzeichnet, dass man die erhaltene freie Verbindung in ihre Salze umwandelt. SUBClaims 1. The method according to claim, characterized in that the free compound obtained is converted into its salts. 2. Verfahren nach Patentanspruch, dadurch ge kennzeichnet, dass man erhaltene Salze in die freie Verbindung umwandelt. 2. The method according to claim, characterized in that one obtained salts in the free Connection converts.
CH1103062A 1962-09-18 1962-09-18 Process for the preparation of the new N- (2-chloro-ethyl) -N '- (5-nitro-thiazolyl-2) -urea CH451156A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CH1103062A CH451156A (en) 1962-09-18 1962-09-18 Process for the preparation of the new N- (2-chloro-ethyl) -N '- (5-nitro-thiazolyl-2) -urea

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH1103062A CH451156A (en) 1962-09-18 1962-09-18 Process for the preparation of the new N- (2-chloro-ethyl) -N '- (5-nitro-thiazolyl-2) -urea

Publications (1)

Publication Number Publication Date
CH451156A true CH451156A (en) 1968-05-15

Family

ID=4369330

Family Applications (1)

Application Number Title Priority Date Filing Date
CH1103062A CH451156A (en) 1962-09-18 1962-09-18 Process for the preparation of the new N- (2-chloro-ethyl) -N '- (5-nitro-thiazolyl-2) -urea

Country Status (1)

Country Link
CH (1) CH451156A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026203A1 (en) * 1998-10-30 2000-05-11 Pharmacia & Upjohn S.P.A. 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents
US7125888B2 (en) 2002-05-02 2006-10-24 Merck & Co., Inc. Tyrosine kinase inhibitors
US7265134B2 (en) 2001-08-17 2007-09-04 Merck & Co., Inc. Tyrosine kinase inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026203A1 (en) * 1998-10-30 2000-05-11 Pharmacia & Upjohn S.P.A. 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents
US7265134B2 (en) 2001-08-17 2007-09-04 Merck & Co., Inc. Tyrosine kinase inhibitors
US7125888B2 (en) 2002-05-02 2006-10-24 Merck & Co., Inc. Tyrosine kinase inhibitors

Similar Documents

Publication Publication Date Title
DE1795699C3 (en)
DE1445186C3 (en) 3,3'-di-2-imidazolin-2-yl-carbanilide
DE2129960C2 (en) Therapeutic compositions containing thioureido derivatives, processes for their preparation and the thioureido derivatives
DE1445632C3 (en) 1-square bracket on 5-nitrothiazolyl- (2) square bracket to-oxotetrahydroimidazole
CH451156A (en) Process for the preparation of the new N- (2-chloro-ethyl) -N '- (5-nitro-thiazolyl-2) -urea
DE2143570A1 (en) Pharmaceutically active ether compounds, processes for their preparation and their use
DE1092021B (en) Process for the preparation of 1- (5-nitro-furfurylidene-amino) -imidazolidin-thione- (2)
CH370765A (en) Process for the production of orally active antidiabetic agents
CH415638A (en) Process for the production of a new urea
CH397640A (en) Process for the preparation of new sulfonylureas
DE1136705B (en) Process for the preparation of 2- (4'-acetylpiperazino) -5-nitrothiazole
DE1014099B (en) Process for the preparation of benzenesulfonyl urethanes
AT220613B (en) Process for the preparation of the new 2- [1 ', 1'-diphenyl-propyl- (3') -amino] -3-phenyl-propane-gluconate
CH460017A (en) Process for the preparation of new nitrothiazole compounds
AT242134B (en) Process for the preparation of new benzimidazole derivatives
AT360973B (en) METHOD FOR PRODUCING NEW BENZOE ACID DERIVATIVES AND THEIR ESTERS AND SALTS
DE1952800B2 (en) 3,6-DIMETHYL-1,2,3,4,4A, 9A-HEXAHYDRO-GAMMA-CARBOLINE-DIHYDROCHLORIDE
AT236941B (en) Process for the preparation of new substituted benzimidazoles and their acid addition salts
AT200155B (en) Process for the production of new sulfonylureas
DE1670441C3 (en) 1 - (5-Nitro-2-thiazolyl) -2-oxotetrahydroimidazoles and processes for their preparation
DE2218787A1 (en) Substituted benzenesulfonamides
DE968485C (en) Process for the production of guanidides of organic sulfonic acids
AT214937B (en) Process for the preparation of new N-arylsulfonyl-N'-tetramethylene ureas
AT236972B (en) Process for the preparation of the new N- (2-chloroethyl) -N '- (5-nitro-thiazolyl-2) -urea and its salts
CH378340A (en) Process for the production of new nitrofurans